Hypertension and diabetes, two interrelated non-communicable diseases, contribute significantly to global morbidity and mortality and often trigger gut microbiota dysbiosis. Gut microbiota-based therapies, particularly probiotics, may serve as an alternative approach to managing hypertension and diabetes. This study aims to explore the therapeutic potential of Lactobacillus plantarum DS1 in modulating hypertension and inflammation by examining its effects on ACE-2 expression, providing a basis for developing probiotic therapy in chronic metabolic disorders. This study used male Wistar rats (Rattus norvegicus), which were maintained for 8 weeks. The Rattus norvegicus rats were split into three groups: group one (C-) was not treated with Lactobacillus plantarum DS1, group (C+) received a high blood sugar but was not given Lactobacillus plantarum DS1, and a treatment group (T) that received 1 mL of Lactobacillus plantarum DS1 every day per oral. Lactobacillus plantarum DS1 significantly reduced random blood sugar levels in the T group (from 241.17 mg/dl to 150.71 mg/dl). The T group showed stable systolic blood pressure (139.83 to 140.17 mmHg) and a slight decrease in diastolic blood pressure (80.33 to 78.50 mmHg), indicating that the treatment may help protect against high blood pressure. Treatment with Lactobacillus plantarum DS1 successfully lowered high ACE-2 levels in the T group, showing that it helps prevent this increase. Therefore, it is concluded that Lactobacillus plantarum DS1 effectively maintains blood pressure, lowers blood sugar, and controls inflammation in diabetic rats. Lactobacillus plantarum DS1 holds significant promise as a therapeutic agent for hypertension and inflammation in individuals with diabetes.
Abdullah et al. (Tue,) studied this question.